

**From:** [REDACTED] (GROW)  
**To:** [REDACTED] @knoxmedical.com  
**Cc:** [REDACTED] (GROW)  
**Subject:** Ares(2019)41569 - RE: Information Request Ingredients Cosmetics  
**Date:** mercredi 9 janvier 2019 17:38:24  
**Attachments:** [image003.png](#)  
[image004.jpg](#)

---

Dear Ms. [REDACTED],

Thank you for your query.

Currently, there are internal discussions concerning cannabis/hemp-related products and we hope to provide you with clarifications in due course. However, we would kindly suggest to visit the CosIng database regularly, in order to follow any developments on cannabis/hemp-related issues.

In addition, we would like to take this opportunity to inform you that the CosIng database is an inventory of cosmetic substances and ingredients, employed for labelling cosmetic products throughout the EU. Please note that ingredient assigned with an INCI name that appears in the inventory section of CosIng does not mean it is to be used in cosmetic products nor approved for such use.

Entry 306 of Annex II to the Cosmetics Regulation 1223/2009 (<https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1493906428740&uri=CELEX:32009R1223>) refers to "Narcotics, natural and synthetic: All substances listed in Tables I and II of the single Convention on narcotic drugs signed in New York on 30 March 1961".

Schedules I and II of the Convention are lists of drugs. According to Art. 1 "definitions" of the convention, "Drug" means any of the substances in Schedules I and II, whether natural or synthetic.

The list of drugs in Schedule I (Schedules as at 16 May 2018: <http://undocs.org/ST/CND/1/Add.1/Rev.4>) includes: CANNABIS and CANNABIS RESIN and EXTRACTS and TINCTURES OF CANNABIS.

Article 1 of the convention defines these terms as follows:

- (b) "Cannabis" means the flowering or fruiting tops of the cannabis plant (excluding the seeds and leaves when not accompanied by the tops) from which the resin has not been extracted, by whatever name they may be designated.
- (c) "Cannabis plant" means any plant of the genus Cannabis,
- (d) "Cannabis resin" means the separated resin, whether crude or purified, obtained from the cannabis plant.

Pursuant to Article 28 ('Control of cannabis') of the 1961 Convention, the 'Convention shall not apply to the cultivation of the cannabis plant exclusively for industrial purposes (fibre and seed) or horticultural purposes'.

Based on the above, ingredients derived from cannabis to the extent that they fall within the

scope of the 1961 Convention should be banned in cosmetic products based on entry 306 of Annex II of the Cosmetics Regulation. It is up to the responsible person to provide the evidence and prove that their product is not falling within the scope of the Convention.

According to the WHO ECDD critical review (<http://www.who.int/medicines/access/controlled-substances/CannabidiolCriticalReview.pdf>), cannabidiol 'is one of the naturally occurring cannabinoids found in cannabis plants. It is a 21-carbon terpenophenolic compound which is formed following decarboxylation from a cannabidiolic acid precursor, although it can also be produced synthetically'.

CBD is not currently a scheduled substance in its own right (only as a component of cannabis extracts). In its letter of July 2018 to the UN Secretary-General (following a critical review of cannabidiol), the WHO recommended that preparations considered to be pure CBD should not be scheduled within the International Drug Control Conventions. In the letter annex, the WHO states that cannabidiol is not specifically listed in the schedules of the UN International Drug Conventions. However, if prepared as an extract or tincture of cannabis it is controlled in Schedule I of the Single Convention on Narcotic Drugs, 1961.

Based on the above, cannabidiol may be prohibited from use in cosmetic products, if it is prepared as an extract of cannabis (and therefore it is up to the responsible person to provide the necessary evidence that their ingredient is not falling under this category).

Please note that the views expressed in this email are not legally binding; only the Court of Justice of the EU can give an authoritative interpretation of Union law.

We hope you will find this information useful.

kind regards

, PhD



**European Commission**

DG for Internal Market, Industry, Entrepreneurship and SMEs  
Unit D4 – Health Technology and Cosmetics

BREY   
B-1049 Brussels/Belgium  
Phone: +32   
E-mail: @ec.europa.eu  
Website: [Cosmetics & Medical Devices](#)

Follow us on

Facebook: [EU Growth](#)

Twitter: [@EU\\_Growth](#)

Our Websites: [ec.europa.eu/growth](#)

[ec.europa.eu/bienkowska](#)

---

**From:** GROW COSMETICS AND MEDICAL DEVICES <GROW-COSMETICS-AND-MEDICAL-DEVICES@ec.europa.eu>  
**Sent:** Friday, January 4, 2019 2:52 PM  
**To:** [REDACTED] (GROW) <[REDACTED]@ec.europa.eu>  
**Subject:** FW: Information Request Ingredients Cosmetics

---

**From:** [REDACTED] <[REDACTED]@knoxmedical.com>  
**Sent:** Monday, December 31, 2018 8:02 PM  
**To:** GROW D4 <GROW-D4@ec.europa.eu>  
**Subject:** Information Request Ingredients Cosmetics

Good evening,

As a representant of Knox Medical, a medical cannabis and hemp company in North America, I am requesting information about the Regulation 1223/2009 on Cosmetics.

We are interested in exporting cosmetics containing hemp oil and CBD, to Europe.


According to my researches, Cannabidiol is listed in Cosing with 4 functions and can therefore be added to cosmetics.

However there is no detailed information on the regulation on what can specifically be added.

For instance can isolate CBD, extracted from hemp be added ? Also is there any limitation or recommendation on the quantity of CBD in cosmetics?

Thank you in advance,

Best Regards,



[REDACTED], KNOX  
+1 (305) [REDACTED] | [REDACTED]@knoxmedical.com  
82 NE 26th St Unit 110, Miami, FL 33137 USA  
[www.knoxmedical.com](http://www.knoxmedical.com)

---

**IMPORTANT:** The information contained in this electronic mail transmission is intended for the use of the named individual or entity to which it is directed and may contain information that is privileged or otherwise confidential. It is not intended for transmission to, or receipt by, anyone other than the named addressee(s). It should not be copied or forwarded to any unauthorized person(s). If you have received this electronic mail transmission in error, please delete it from your system without copying or forwarding it and notify the sender of the error by reply email or by calling Knox Medical at 888-441-KNOX (toll-free), so that we can correct our records.

---